¹⁸F-fallypride and ¹¹C-methionine positron emission tomography/computed tomography for the study of prolactinomas and nonfunctioning pituitary adenomas: A case series

Abstract

Some studies have assessed the expression of dopaminergic dopamine 2 (D2)/3 receptors in prolactinomas and nonfunctioning pituitary adenomas (NFPA) by positron emission tomography/computed tomography (PET/CT) with ¹¹C-raclopride, proving that this modality can be useful to predict the response to treatment with dopamine agonists. However, the use of ¹¹C-labeled radiotracers is limited, as it requires a cyclotron in the PET center. ¹⁸F-fallypride is a radiotracer that has proven useful in assessing the expression of D2/3 receptors. As it is labeled with ¹⁸F, it can be produced and transported to distant PET centers. There are no studies on the usefulness of ¹⁸F-fallypride for the evaluation of patients with prolactinomas and NFPA. The aim of this study was to describe the first case series of patients with prolactinomas and NFPA studied with ¹⁸F-fallypride and ¹¹C-methionine PET/CT to reveal D2/3 expression and amino acid (AA) metabolism. ¹⁸F-fallypride and ¹¹C-methionine uptake were assessed in a case series of six patients, five with prolactinomas and one with a NFPA, and compared with clinical presentation and follow-up at 6–18 months. All patients presented with macroadenomas, with a wide range of AA metabolism, as revealed by ¹¹C-methionine PET/CT. ¹⁸F-fallypride PET/CT identified low to moderate/high D2/3 expression in the tumors. The patient that presented low expression of D2/3 in the tumor and high AA metabolism showed a poor response to DA therapy. ¹⁸F-fallypride was able to reveal D2/3 receptor expression in prolactinomas and NFPA, with the advantage of been a more accessible radiotracer in comparison with previous ¹¹C labeled analogs.

Keywords

¹¹C-methionine - ¹⁸F-fallypride - nonfunctioning adenoma - positron emission tomography - prolactinoma

Financial support and sponsorship

Nil.

Publikationsverlauf

Eingereicht: 17. Juni 2020

Angenommen: 10. September 2020

Artikel online veröffentlicht:
24. März 2022

• References

• 1 Chanson P, Maiter D. The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new. Best Pract Res Clin Endocrinol Metab 2019;33:101290.
• 2 Pirker W, Riedl M, Luger A, Czech T, Rössler K, Asenbaum S, et al. Dopamine D2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT. J Nucl Med 1996;37:1931-7.
• 3 De Herder WW, Reijs AE, De Swart J, Kaandorp Y, Lamberts SW, Krenning EP, et al. Comparison of iodine-123 epidepride and iodine-123 IBZM for dopamine D, receptor imaging in clinically non-functioning pituitary macroadenomas and macroprolactinomas. Eur J Nucl Med 1999;26:46-50.
• 4 Bergström M, Muhr C, Lundberg PO, Långström B. PET as a tool in the clinical evaluation of pituitary adenomas. J Nucl Med 1991;32:610-5.
• 5 Colao A, Ferone D, Lastoria S, Cerbone G, Di Sarno A, Di Somma C, et al. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: Predictive value of pituitary scintigraphy with 123I-methoxybenzamide. Clin Endocrinol (Oxf) 2000;52:437-45.
• 6 Iglesias P, Cardona J, Díez JJ. The pituitary in nuclear medicine imaging. Eur J Intern Med 2019;68:6-12.
• 7 Bergström M, Muhr C, Lundberg PO, Bergström K, Lundqvist H, Antoni G, et al. Amino acid distribution and metabolism in pituitary adenomas using positron emission tomography with D-[11C] methionine and L-[11C] methionine. J Comput Assist Tomogr 1987;11:384-9.
• 8 Tang BN, Levivier M, Heureux M, Wikler D, Massager N, Devriendt D, et al. ¹¹C-methionine PET for the diagnosis and management of recurrent pituitary adenomas. Eur J Nucl Med Mol Imaging 2006;33:169-78.
• 9 Rodriguez-Barcelo S, Gutierrez-Cardo A, Dominguez-Paez M, Medina-Imbroda J, Romero-Moreno L, Arraez-Sanchez M. Clinical usefulness of coregistered ¹¹C-methionine positron emission tomography/3-T magnetic resonance imaging at the follow-up of acromegaly. World Neurosurg 2014;82:468-73.
• 10 Muhr C, Bergström M, Lundberg PO, Bergström K, Hartvig P, Lundqvist H, et al. Dopamine receptors in pituitary adenomas: PET visualization with ¹¹C-N-methylspiperone. J Comput Assist Tomogr 1986;10:175-80.
• 11 de Herder WW, Reijs AEM, Feelders RA, van Aken MO, Krenning EP, van der Lely AJ, et al. Diagnostic imaging of dopamine receptors in pituitary adenomas. Eur J Endocrinol 2007;156 (suppl 1):S53-6.
• 12 Stoessl AJ. Neuroimaging in Parkinson's disease: From pathology to diagnosis. Parkinsonism Relat Disord 2012;18 (suppl 1):S55-9.
• 13 Mukherjee J, Christian BT, Dunigan KA, Shi B, Narayanan TK, Satter M, et al. Brain imaging of ¹⁸F-fallypride in normal volunteers: Blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors. Synapse 2002;46:170-88.
• 14 Kim JH, Cumming P, Son YD, Hang-Keun K, Yo-Han J, Jong-Hoon K, et al. Altered connectivity between striatal and extrastriatal regions in patients with schizophrenia on maintenance antipsychotics: an [18F] fallypride PET and functional MRI study. Synapse 2018;72:e22064.
• 15 Li P, Gui S, Cao L, Hua L, Jiwei B, Chuzhong L, et al. Use of micro-positron emission tomography with¹⁸F-fallypride to measure the levels of dopamine receptor-D2 and ¹⁸F-FDG as molecular imaging tracer in the pituitary glands and prolactinomas of Fischer-344 rats. Onco Targets Ther 2016;9:2057-68.
• 16 Bergström M, Muhr C, Lundberg PO, Långström B. et al. PET as a tool in the clinical evaluation of pituitary adenomas. J Nucl Med 1991;32:610-5. Available from: https://pubmed.ncbi.nlm.nih.gov/2013801/.
• 17 Slifstein M, Kegeles LS, Xu X, Thompson JL, Urban N, Castrillon J, et al. Striatal and extrastriatal dopamine release measured with PET and [18F] fallypride. Synapse 2010;64:350-62.
• 18 Laruelle M, Slifstein M, Huang Y. Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography. Mol Imaging Biol 2003;5:363-75.
• 19 Thorner MO, Schran HF, Evans WS, Rogol AD, Morris JL, MacLeod RM, et al. A broad spectrum of prolactin suppression by bromocriptine in hyperprolactinemic women: A study of serum prolactin and bromocriptine levels after acute and chronic administration of bromocriptine. J Clin Endocrinol Metab 1980;50:1026-33.
• 20 Wu ZB, Zheng WM, Su ZP, Chen Y, Wu JS, Wang CD, et al. Expression of D2RmRNA isoforms and ERmRNA isoforms in prolactinomas: Correlation with the response to bromocriptine and with tumor biological behavior. J Neurooncol 2010;99:25-32.
• 21 Seok H, Lee EY, Choe EY, Yang WI, Kim JY, Shin DY, et al. Analysis of ¹⁸F-fluorodeoxyglucose positron emission tomography findings in patients with pituitary lesions. Korean J Intern Med 2013;28:81-8.
• 22 Wang H, Hou B, Lu L, Feng M, Zang J, Yao S, et al. PET/MRI in the Diagnosis of Hormone-Producing Pituitary Microadenoma: A Prospective Pilot Study. J Nucl Med 2018;59:523-8.
• 23 Feng Z, He D, Mao Z, Wang Z, Zhu Y, Zhang X, et al. Utility of ¹¹C-methionine and ¹⁸F-FDG PET/CT in patients with functioning pituitary adenomas. Clin Nucl Med 2016;41:e130-4.
• 24 D'Amico A, Stąpór-Fudzińska M, Tarnawski R. CyberKnife radiosurgery planning of a secreting pituitary adenoma performed with 68Ga DOTATATE PET and MRI. Clin Nucl Med 2014;39:1043-4.
• 25 Parghane RV, Agrawal K, Mittal BR, Shukla J, Bhattacharya A, Mukherjee KK. 68Ga DOTATATE PET/CT in a rare coexistence of pituitary macroadenoma and multiple paragangliomas. Clin Nucl Med 2014;39:91-3.
• 26 Basu S, Ranade R, Hazarika S. 68Ga DOTATATE PET/CT of Synchronous Meningioma and Prolactinoma. Clin Nucl Med 2016;41:230-1.
• 27 Zhao X, Xiao J, Xing B, Wang R, Zhu Z, Li F. Comparison of (68) Ga DOTATATE to ¹⁸F-FDG uptake is useful in the differentiation of residual or recurrent pituitary adenoma from the remaining pituitary tissue after transsphenoidal adenomectomy. Clin Nucl Med 2014;39:605-8.